Clinical Trials Logo

Clinical Trial Summary

This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG who previously participated in Study AT-007-1001 Part D and/or Part D Extension. The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects with CG will also be evaluated.


Clinical Trial Description

Primary: - To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with Classic Galactosemia (CG) Secondary: - To evaluate the long-term inhibition of galactitol, a biomarker of aldose reductase (AR) activity, induced by 12-month oral administration of AT-007 to adult subjects with CG - To evaluate the pharmacokinetic (PK) parameters of 12-month oral administration of AT-007 in adult subjects with CG Exploratory: - To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG - To evaluate the burden of illness (BOI) of adult subjects with CG - To evaluate quality of life (QOL) measures of adult subjects with CG - To evaluate the effect of 12-month oral administration of AT-007 on the BOI and QOL of adult subjects with CG ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05418829
Study type Interventional
Source Applied Therapeutics, Inc.
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 1, 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03838016 - Preventing Speech and Language Disorders in Children With Classic Galactosemia N/A
Active, not recruiting NCT04902781 - Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia Phase 2/Phase 3
Completed NCT04117711 - Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia Phase 1/Phase 2
Completed NCT03580122 - The Effect of Arginine on Classic Galactosemia Phase 2